DHR Earnings

DHR reported its earnings on 2026-01-28, showcasing a revenue of 7.00B against an estimate of 7.00B, resulting in a 0.71% surprise. The EPS was 2.23, surpassing the expected 2.22 by 0.45% . The stock experienced a -4.76% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DHR's earnings announcement on 2026-01-28, the stock price moved by -4.76% on the day of the release. Over the subsequent five days, it saw a % change. Historically, DHR's stock price tends to shift by an average of +0.14% in the 10 days leading up to earnings and -1.61% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate DHR’s annual revenue to reach 6.00B, while the EPS is projected at 2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.01% and EPS estimates Revise Upward by 0.01% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between DHR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.01%, while EPS estimates moved Revise Upward by 0.01% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DHR's stock price typically moves by +0.14% in the 10 days before its earnings and -1.61% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 2.00 and revenue of 6.00B.

The earnings call indicates strong performance in diagnostics and bioprocessing, with solid free cash flow and revenue growth in key segments. Guidance for 2026 suggests continued growth, supported by strategic initiatives and cost savings. Analysts' questions reveal confidence in the company's strategy, despite some uncertainties in specific areas. Overall, the positive outlook, especially in bioprocessing and diagnostics, and expected margin improvements suggest a positive stock price movement.